Cargando…

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

The emergence of human intratumoural immunotherapy (HIT-IT) is a major step forward in the management of unresectable melanoma. The direct injection of treatments into melanoma lesions can cause cell lysis and induce a local immune response, and might be associated with a systemic immune response. D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Middleton, Mark R., Hoeller, Christoph, Michielin, Olivier, Robert, Caroline, Caramella, Caroline, Öhrling, Katarina, Hauschild, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492252/ https://www.ncbi.nlm.nih.gov/pubmed/32713938 http://dx.doi.org/10.1038/s41416-020-0994-4

Ejemplares similares

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Intratumoural administration and tumour tissue targeting of cancer immunotherapies
por: Melero, Ignacio, et al.
Publicado: (2021)

Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
por: Hoeller, Christoph, et al.
Publicado: (2016)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors
por: Agrawal, Sudhir, et al.
Publicado: (2019)

Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts
por: Graff, B A, et al.
Publicado: (2003)

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
por: Naito, Yoichi, et al.
Publicado: (2023)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

Multidimensional intratumour heterogeneity in neuroblastoma
por: von Stedingk, Kristoffer, et al.
Publicado: (2019)

Intratumour microbiome of pancreatic cancer
por: Guan, Shi-Wei, et al.
Publicado: (2023)

The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma
por: Evan, Theodore, et al.
Publicado: (2022)

Metastatic melanoma – a review of current and future drugs
por: Velho, Tiago Rodrigues
Publicado: (2012)

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021)

Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma
por: Olszanski, Anthony J.
Publicado: (2014)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines
por: Czarnecka, Anna M., et al.
Publicado: (2022)

Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma
por: Yeh, Jennifer E., et al.
Publicado: (2022)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival
por: Donskov, F, et al.
Publicado: (2002)

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
por: van Akkooi, Alexander C. J., et al.
Publicado: (2020)

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
por: Ozaki, Kai, et al.
Publicado: (2021)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
por: Ellis, Hayley P., et al.
Publicado: (2015)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Local hypoxia is produced at sites of intratumour injection
por: Olive, P L, et al.
Publicado: (2002)

Intrahepatic fetus: unusual image of an intratumoural haemorrhage
por: Reyes, Queennie, et al.
Publicado: (2017)

Producing the appropriate model and drug for intratumoural ablation
por: Kosmidis, Christoforos, et al.
Publicado: (2020)

Intratumoural microbiota: from theory to clinical application
por: Ji, Hao, et al.
Publicado: (2023)

Current application of immunotherapy in melanoma
por: Xie, Ruxin, et al.
Publicado: (2023)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives
por: Motta, Rodrigo, et al.
Publicado: (2021)

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions
por: David, Steven, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qqmu2av0errj2363d2qg4ueo3l